Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,001–1,100 of 4,628
Doliner, B., Rodriguez, K., Montesi, S. B., Fu, X., Sharma, A., & Wallace, Z. S. (2022) · Rheumatology · doi:10.1093/rheumatology/keac339 · Cited by 43
The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions
Behr, J., Salisbury, M. L., Walsh, S. L. F., Podolanczuk, A. J., Hariri, L. P., Hunninghake, G. M., Kolb, M. R. J., Ryerson, C. J., Cottin, V., Beasley, M. B., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0048pp · Cited by 49
Self-citationDefining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis
Calver, J., Parmar, N. R., Harris, G., Lithgo, R. M., Stylianou, P., Zetterberg, F. R., Gooptu, B., MacKinnon, A. C., Carr, S. B., Borthwick, L. A., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107300 · Cited by 50
Yu, Y., Wu, N., Chuang, C.-C., Wang, R., Pan, X., Benjamin, N. N., Devercelli, G., & Coultas, D. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.4.414 · Cited by 44
Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
Vainshelboim, B. (2016) · Breathe · doi:10.1183/20734735.006916 · Cited by 52
Larsen, B. T., Smith, M. L., Elicker, B. M., Fernández, J., Arbo, G., Pereira, C. A. C., & Leslie, K. O. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0299-sa · Cited by 42
Liang, Z., Hoffman, L. A., Nouraie, M. S., Kass, D. J., Donahoe, M. P., Gibson, K. F., Saul, M. I., & Lindell, K. O. (2016) · Journal of Palliative Medicine · doi:10.1089/jpm.2016.0258 · Cited by 47
Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines
Чучалин, А. Г., Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Демура, Т. А., Ilkovich, M. M., Коган, Е. А., Samsonova, M. V., Speranskaya, A. A., Tyurin, I. E., et al. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-4-399-419 · Cited by 49
Mooney, J. J., Raimundo, K., Chang, E. Y., & Broder, M. S. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0426-2 · Cited by 48
Therapeutic antibodies: A new era in the treatment of respiratory diseases?
Sécher, T., Guilleminault, L., Reckamp, K. L., Amanam, I. U., Plantier, L., & Heuzé‐Vourc'h, N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.003 · Cited by 45
Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis
Kim, Y.-I., Shin, H., Chun, Y., Cho, C., Koh, J., Chung, D. H., & Park, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0530-0 · Cited by 47
Tullemans, B. M. E., Heemskerk, J. W. M., & Kuijpers, M. J. E. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14225 · Cited by 51
Graney, B. A., & Lee, J. S. (2018) · Patient Related Outcome Measures · doi:10.2147/prom.s144425 · Cited by 44
Lee, S. H., Yeo, Y., Kim, T., Lee, H. L., Lee, J. H., Park, Y. B., Park, J. S., Kim, Y. H., Song, J. W., Jhun, B. W., et al. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0091 · Cited by 50
Self-citationMobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis
Marcoux, V. S., Wang, M., Burgoyne, S., Fell, C. D., Ryerson, C. J., Sajobi, T. T., & Johannson, K. A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201904-335rl · Cited by 41
The Role of Airway Myofibroblasts in Asthma
Jendzjowsky, N. G., & Kelly, M. M. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.1917 · Cited by 46
Increased flux through the mevalonate pathway mediates fibrotic repair without injury
Larson‐Casey, J. L., Vaid, M., Gu, L., He, C., Cai, G.-Q., Ding, Q., Davis, D., Berryhill, T. F., Wilson, L. S., Barnes, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127959 · Cited by 46
Rozenberg, D., Sitzer, N., Porter, S., Weiss, A. J., Colman, R., Reid, W. D., Shapera, S., Fisher, J. H., & Wentlandt, K. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.12.364 · Cited by 43
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Lasky, J. A., Criner, G. J., Lazarus, H. M., KOHLBRENNER, V. M., Bender, S. D., & Richeldi, L. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01452-5 · Cited by 45
“On the basis of the mechanism of action of nintedanib [9, 10] and data from clinical trials [4, 5], the following were defined as adverse events of special interest: diarrhea (MedDRA preferred term), liver enzyme and bilirubin elevations including drug-induced liver injury (based on the SMQs ‘‘drug related hepatic dis…”
BackgroundSelf-citationShaish, H. A., Ahmed, F. S., Lederer, D. J., D’Souza, B. M., Armenta, P. M., Salvatore, M. M., Saqi, A., Huang, S., Jambawalikar, S., & Mutasa, S. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202001-068oc · Cited by 40
Ellison, G. M., Colley, L. S., O’Brien, K. A., Roberts, K. A., Agbaedeng, T. A., & Ross, M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.602183 · Cited by 43
“Clinical trials with anti-fibrotic agents have shown promise in reversing progression of pulmonary fibrosis, as evidenced with nintedanib (247) and pirfenidone (248), which were approved by the FDA more than 6 years ago (249).”
BackgroundThe Diagnosis and Treatment of Pulmonary Fibrosis
Kreuter, M., Müller-Ladner, U., Costabel, U., Jonigk, D. D., & Heußel, C. P. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0018 · Cited by 57
Self-citationXu, F., Tanabe, N., Vasilescu, D. M., McDonough, J. E., Coxson, H. O., Ikezoe, K., Kinose, D., Ng, K. W., Verleden, S. E., Wuyts, W. A., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103325 · Cited by 46
“Anti-fibrotic therapies slow the rate of lung function decline in persons with IPF [6,7], but none of the currently available therapies consistently improve the quality of life associated with an established diagnosis of IPF.”
BackgroundPopmihajlov, Z., Sutherland, D., Horan, G. S. B., Ghosh, A., Lynch, D. A., Noble, P. W., Richeldi, L., Reiss, T. F., & Greenberg, S. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001060 · Cited by 50
Self-citationInhibition of RUNX1 blocks the differentiation of lung fibroblasts to myofibroblasts
Dubey, S., Dubey, P. K., Umeshappa, C. S., Ghebre, Y. T., & Krishnamurthy, P. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30684 · Cited by 45
New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics
Ebata, S., Yoshizaki‐Ogawa, A., Sato, S., & Yoshizaki, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154631 · Cited by 43
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient
Meyer, K. C., Danoff, S. K., LANCASTER, L. H., & Nathan, S. D. (2015) · CHEST Journal · doi:10.1378/chest.14-2475 · Cited by 46
Modeling Extracellular Matrix-Cell Interactions in Lung Repair and Chronic Disease
Hackett, T., & Osei, E. T. (2021) · Cells · doi:10.3390/cells10082145 · Cited by 52
Seeliger, B., Carleo, A., Wendel‐Garcia, P. D., Fuge, J., Montes‐Worboys, A., Schuchardt, S., Molina‐Molina, M., & Prasse, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837680 · Cited by 44
“Pirfenidone and nintedanib attenuate the mean decline in forced vital capacity significantly to a similar extent (King et al., 2014; Richeldi et al., 2014; Raghu et al., 2015).”
BackgroundPulmonary hypertension in interstitial lung disease: an area of unmet clinical need
Dhont, S., Zwaenepoel, B. A. C., Vandecasteele, E. H., Brusselle, G., & Pauw, M. D. (2022) · ERJ Open Research · doi:10.1183/23120541.00272-2022 · Cited by 48
Ogura, T., Inoue, Y., Azuma, A., Homma, S. A., Kondoh, Y., Tanaka, K., Ochiai, K., Sugiyama, Y., & Nukiwa, T. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02411-y · Cited by 48
Self-citationKataoka, K., Nishiyama, O., Ogura, T., Mori, Y., Kozu, R., Arizono, S., Tsuda, T., Tomioka, H., Tomii, K., Sakamoto, K., et al. (2023) · Thorax · doi:10.1136/thorax-2022-219792 · Cited by 41
Mochizuka, Y., Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Inoue, Y., Yasui, H., Hozumi, H., Karayama, M., et al. (2023) · Respirology · doi:10.1111/resp.14523 · Cited by 41
Self-citationInjured Endothelial Cell: A Risk Factor for Pulmonary Fibrosis
Zhao, W., Wang, L., Wang, Y., Yuan, H., Zhao, M., Lian, H., Ma, S., Xu, K., Li, Z., & Yu, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108749 · Cited by 47
“In a clinical trial, researchers have reported that nintedanib significantly recovers the forced vital capacity (FVC) of IPF patients over the 52-week treatment [105].”
BackgroundRicheldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martínez, F. J., Oldham, J. M., Valenzuela, C., Gordat, M., Liu, Y., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001563 · Cited by 46
Self-citationNintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
Azuma, A., Inomata, M., & Nishioka, Y. (2015) · Core evidence · doi:10.2147/ce.s82905 · Cited by 57
Self-citationLung transplantation in IIP : A review
Brown, A. W., Kaya, H., & Nathan, S. D. (2015) · Respirology · doi:10.1111/resp.12691 · Cited by 44
Outcome Measures for Clinical Trials in Interstitial Lung Diseases
Lammi, M. R., Baughman, R. P., Birring, S. S., Russell, A., Ryu, J. H., Scholand, M. B., Distler, O., LeSage, D., Sarver, C., Antoniou, K. M., et al. (2015) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x11666150619183527 · Cited by 43
Pompe, E., de Jong, P. A., Lynch, D. A., Leßmann, N., Išgum, I., van Ginneken, B., Lammers, J. J., & Hoesein, F. A. A. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01814-2016 · Cited by 40
Airway Complications After Lung Transplantation
Frye, L., & Machuzak, M. S. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.07.010 · Cited by 43
Clukers, J., Lanclus, M., Mignot, B., Holsbeke, C. S. V., Roseman, J., Porter, S., Gorina, E., Kouchakji, E., Lipson, K. E., Backer, W. D., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0918-5 · Cited by 45
Distler, O., Volkmann, E. R., Hoffmann‐Vold, A., & Maher, T. M. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1668269 · Cited by 43
“Nintedanib was investigated as a potential treatment for SSc-ILD based on the clinical and mechanistic similarities between IPF and SSc-ILD [51].”
BackgroundInfluentialYoshikawa, T., Otsuka, M., Chiba, H., Ikeda, K., Mori, Y., Umeda, Y., Nishikiori, H., Kuronuma, K., & Takahashi, H. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1060-y · Cited by 40
Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis
Chen, W., Chen, N., Chen, H., Yu, W.-K., Su, V. Y., Chen, H., Wu, H.-H., & Yang, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134735 · Cited by 48
“In clinical trials, nintedanib led to a significant reduction in the rate of decline in pulmonary function in patients with IPF, reduced the time to the first acute exacerbation, and slowed disease progression with acceptable tolerability and safety [23,24].”
BackgroundGuler, S. A., Clarenbach, C., Brutsche, M. H., Hostettler, K., Brill, A.-K., Schertel, A., Geiser, T. K., & Funke-Chambour, M. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-266oc · Cited by 39
Smith, M. L. (2021) · Modern Pathology · doi:10.1038/s41379-021-00889-5 · Cited by 49
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
Lescoat, A., Roofeh, D., Kuwana, M., Lafyatis, R., Allanore, Y., & Khanna, D. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08891-0 · Cited by 41
Real-life prevalence of progressive fibrosing interstitial lung diseases
Gagliardi, M., Berg, D. V., Heylen, C. E., Koenig, S., Hoton, D., Tamirou, F., Pieters, T., Ghaye, B., & Froidure, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-03481-8 · Cited by 43
Interstitial pneumonia with autoimmune features: challenges and controversies
Mackintosh, J. A., Wells, A. U., Cottin, V., Nicholson, A. G., & Renzoni, E. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0177-2021 · Cited by 42
Self-citationShen, H., Zhang, N., Liu, Y., Yang, X., He, Y., Li, Q., Shen, X., Zhu, Y., & Yang, Y. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.805535 · Cited by 43
“Anti-Fibrosis Drugs Multiple studies (Noble et al., 2011; Richeldi et al., 2011; Richeldi et al., 2014; Myllarniemi and Kaarteenaho, 2015; Margaritopoulos et al., 2016)have shown that currently available anti-fibrosis drugs nintedanib and pirfenidone can significantly reduce the decline rate of pulmonary function and…”
BackgroundKewalramani, N., Machahua, C., Poletti, V. E., Cadranel, J. L., Wells, A. U., & Funke-Chambour, M. (2022) · ERJ Open Research · doi:10.1183/23120541.00115-2022 · Cited by 45
Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs
Nishikiori, H., Kuronuma, K., Hirota, K., Yama, N., Suzuki, T., Onodera, M., Onodera, K., Ikeda, K., Mori, Y., Asai, Y., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02269-2021 · Cited by 42
Khoo, J. K., Montgomery, A. B., Otto, K. L., Surber, M., Faggian, J., Lickliter, J. D., & Glaspole, I. (2020) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2018.1507 · Cited by 40
Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Roach, K., Castells, E., Dixon, K., Mason, S., Elliott, G., Marshall, H., Poblocka, M., Macip, S., Richardson, M., Khalfaoui, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679388 · Cited by 39
“However, pirfenidone did not increase the gene expression of any pro-fibrotic molecules, and thus while exhibiting potentially less anti-fibrotic activity than nintedanib in human lung tissue, it did not counteract these inhibitory effects, which may explain why it is as effective as nintedanib clinically (King et al.…”
BackgroundSong, J. W., Ogura, T., Inoue, Y., Xu, Z., Quaresma, M., Stowasser, S., Stansen, W., & Crestani, B. (2020) · Respirology · doi:10.1111/resp.13647 · Cited by 39
Self-citationSun, X., Cui, X., Chen, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110744 · Cited by 39
Τzouvelekis, Α., Antoniou, K. M., Kreuter, M., Evison, M., Blum, T. G., Poletti, V. E., Grigoriu, B. D., Vancheri, C., Spagnolo, P., Karampitsakos, Τ., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00529-2020 · Cited by 43
Self-citationNtatsoulis, K., Karampitsakos, Τ., Tsitoura, E., Stylianaki, E.-A., Matralis, A. N., Tzouvelekis, A., Antoniou, K. M., & Aidinis, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687397 · Cited by 45
Fainberg, H. P., Oldham, J. M., Molyneaux, P. L., Allen, R. J., Kraven, L. M., Fahy, W. A., Porte, J., Braybrooke, R., Saini, G., Karsdal, M. A., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00173-x · Cited by 46
“2,3 7 Identifying and characterising pulmonary function trajectories soon after diagnosis 3 is crucial for establishing prognosis, making clinical management decisions, 2,3,6,7 and interpreting results from interventional clinical trials.”
Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases
Ferguson, L. T., Ma, X., Myerson, J. W., Wu, J., Glassman, P. M., Zamora, M. E., Hood, E. D., Zaleski, M. H., Shen, M., Essien, E., et al. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200106 · Cited by 56
Stenzel, W., Mammen, A. L., Gallay, L., Holzer, M., Kleefeld, F., Benvéniste, O., Allenbach, Y., Allenbach, Y., Benvéniste, O., Damoiseaux, J. G. M. C., et al. (2024) · Neuromuscular Disorders · doi:10.1016/j.nmd.2024.104453 · Cited by 45
Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
Case, A. H., & Johnson, P. (2017) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000192 · Cited by 46
Keenan, C. R., Langenbach, S. Y., Jativa, F., Harris, T., Li, M., Chen, Q., Xia, Y., Gao, X., Schuliga, M. J., Jaffar, J., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00738 · Cited by 43
Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth
Zhang, W., Zhao, J.-M., Lin, J., Hu, C.-Z., Zhang, J., YANG, W.-L., Zhang, J., Zhang, J., & Zhu, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.103 · Cited by 44
Tsai, M., Chang, W., Liao, S., Chang, K., Sheu, C., & Kuo, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081958 · Cited by 42
Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
Jo, H. E., Corte, T. J., Glaspole, I., Grainge, C., Hopkins, P. M.-A., Moodley, Y. P., Reynolds, P. N., Chapman, S. A., Walters, E. H., Zappala, C. J., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0846-2 · Cited by 42
Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis
O'Brien, E. C., Hellkamp, A. S., Neely, M. L., Swaminathan, A. C., Bender, S. D., Snyder, L. D., Culver, D. A., Conoscenti, C., Todd, J. L., Palmer, S. M., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2019.11.042 · Cited by 43
Self-citationS2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
Behr, J., Günther, A., Bonella, F., Dinkel, J., Fink, L., Geiser, T., Geissler, K. H., Gläser, S., Handzhiev, S., Jonigk, D. D., et al. (2021) · Respiration · doi:10.1159/000512315 · Cited by 42
Self-citationHou, J., Ji, Q., Ji, J., Ju, S., Xu, C., Yong, X., Xu, X., Muddassir, M., Chen, X., Xie, J., et al. (2021) · Theranostics · doi:10.7150/thno.54217 · Cited by 45
Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
Nasser, M., Si-Mohamed, S. A., Turquier, S., Traclet, J., Ahmad, K., Philit, F., Bonniaud, P., Chalabreysse, L., Thivolet-Béjui, F., & Cottin, V. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02043-5 · Cited by 44
Self-citationNatural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis
Hasan, M., Paul, N. C., Paul, S. K., Saikat, A. S. M., Akter, H., Mandal, M., & Lee, S. (2022) · Molecules · doi:10.3390/molecules27051481 · Cited by 46
Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics
Fujita, Y. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00210-0 · Cited by 41
Swaminathan, A. C., Hellkamp, A. S., Neely, M. L., Bender, S. D., Paoletti, L., White, E. S., Palmer, S. M., Whelan, T. P. M., & Dilling, D. F. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202105-589oc · Cited by 44
Raman, L., Stewart, I. D., Barratt, S. L., Chua, F., Chaudhuri, N., Crawshaw, A., Gibbons, M., Hogben, C., Hoyles, R. K., Kouranos, V., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00423-2022 · Cited by 43
Deng, L., Ouyang, B., Tang, W., Wang, N., Yang, F., Shi, H., Zhang, Z., Yu, H., Chen, M., Wei, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155687 · Cited by 45
Zhang, Y., Liu, J., Zheng, R., Hou, K., Zhang, Y., Jia, T., Lu, X., Samarawickrama, P. N., Jia, S., He, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155882 · Cited by 49
Bhardwaj, S., Gautam, R. K., & Kushwaha, S. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.08.003 · Cited by 55
Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis
Todd, N. W., Atamas, S. P., Luzina, I. G., & Galvin, J. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1067609 · Cited by 40
Matsushima, S., & Ishiyama, J. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00252.2016 · Cited by 38
Yamauchi, H., Bando, M., Baba, T., Kataoka, K., Yamada, Y., Yamamoto, H., Miyamoto, A., Ikushima, S., Johkoh, T., Sakai, F., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166168 · Cited by 38
Etiology and treatment of cough in idiopathic pulmonary fibrosis
Vigeland, C. L., Hughes, A. H., & Horton, M. R. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.12.016 · Cited by 42
Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma
Kurimoto, R., Ebata, T., Iwasawa, S., Ishiwata, T., Tada, Y., Tatsumi, K., & Takiguchi, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6188 · Cited by 42
Severe idiopathic pulmonary fibrosis: what can be done?
Caminati, A., Cassandro, R., Torre, O., & Harari, S. A. (2017) · European Respiratory Review · doi:10.1183/16000617.0047-2017 · Cited by 39
Ohkubo, H., Nakagawa, H., & Niimi, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.10.003 · Cited by 44
Decoding fibrosis: Mechanisms and translational aspects
Schaefer, L. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.009 · Cited by 40
Biologic Treatments in Interstitial Lung Diseases
Karampitsakos, Τ., Vraka, A., Bouros, D. E., Liossis, S. C., & Τzouvelekis, Α. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00041 · Cited by 39
Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis
Okamoto, M., Izuhara, K., Ohta, S., Ono, J., & Hoshino, T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-6657-4_9 · Cited by 36
Hozumi, H., Kono, M., Hasegawa, H., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., Inui, N., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.01.083 · Cited by 43
Belhassen, M., Dalon, F., Nolin, M., & Van Ganse, E. (2021) · Respiratory Research · doi:10.1186/s12931-021-01714-y · Cited by 38
Gerckens, M., Schorpp, K., Pelizza, F., Wögrath, M., Reichau, K., Ma, H., Dworsky, A.-M., Sengupta, A., Stoleriu, M. G., Heinzelmann, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3673 · Cited by 37
Epidemiology and real-life experience in progressive pulmonary fibrosis
Valenzuela, C., & Cottin, V. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000908 · Cited by 37
Self-citationHou, J., Huang, Y. L., Fu, L., Sun, M., Wang, L., Guo, R., Chen, L., & Lv, C. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03640 · Cited by 38
Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds
Kim, K. K., Sisson, T. H., & Horowitz, J. C. (2016) · The Journal of Pathology · doi:10.1002/path.4825 · Cited by 39
The clinical impact of major comorbidities on idiopathic pulmonary fibrosis
Suzuki, A., & Kondoh, Y. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2016.11.004 · Cited by 46
Lü, W., Yao, X., Ouyang, P., Dong, N., Wu, D., Jiang, X., Wu, Z., Zhang, C., Xu, Z., Tang, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01507 · Cited by 44
P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis
Müller, T., Fay, S., Vieira, R. P., Karmouty‐Quintana, H., Cicko, S., Ayata, C. K., Zissel, G., Goldmann, T., Lungarella, G., Ferrari, D., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01028 · Cited by 42
Nintedanib for Idiopathic Pulmonary Fibrosis
Tepede, A. K., & Yogaratnam, D. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017735242 · Cited by 40
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
Schmid, U., Döge, C., Dallinger, C., & Freiwald, M. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.11.004 · Cited by 38
Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA
Noth, I., Oelberg, D., Kaul, M., Conoscenti, C., & Raghu, G. (2018) · European Respiratory Journal · doi:10.1183/13993003.02106-2017 · Cited by 41
Self-citationFen, F., Zhang, J., Wang, Z., Wu, Q., & Zhou, X. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7579 · Cited by 62
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.